Developer docs
API playgroundTry for free, no card

Search company profiles

FIRE1

Full company profile

uuid00007nv

Namestring
FIRE1
Legal namestring
Foundry Innovation & Research 1, Limited
Company typeenum
Private
Founded yearint
2016
Descriptiontext

FIRE1 (legal entity Foundry Innovation & Research 1, Limited) is a privately held medical device company headquartered in Dublin, Ireland, developing the NORM System for physician-directed self-management of heart failure. The NORM platform comprises an implantable sensor placed in the inferior vena cava (IVC) that directly measures cross-sectional area changes as a proxy for intravascular fluid volume, a wearable NORM Belt worn briefly each day to activate the sensor and wirelessly transmit data, and cloud-connected NORM Patient and Clinician Apps that surface daily readings and intervention alerts. Unlike pressure-based cardiac monitoring approaches, NORM's direct IVC-area measurement is positioned as a first-in-class mechanism for detecting early fluid accumulation, enabling lifestyle and medication adjustments to prevent decompensation and hospitalization.

The company targets two end-user segments: heart failure patients (particularly those over 65, the population driving most heart failure hospitalizations) and the cardiologists and heart failure specialists who manage them. FIRE1 conducts clinical trials across the US (Columbia, Duke, Ohio State, Rochester General, St David's), the UK (Royal Bournemouth, Golden Jubilee, Royal Brompton, University Hospitals Leicester), Ireland (University Hospital Galway), and the Netherlands (University Medical Center Groningen, Erasmus), building evidence for future regulatory submissions. The product remains investigational and is not yet approved for clinical use in any geography, so no commercial revenue is currently generated.

FIRE1's revenue model is expected to be hardware-led once regulatory approval is secured: device sales of the NORM System (sensor plus belt) to healthcare systems and cardiac catheterization labs, with possible associated monitoring services. The go-to-market approach targets healthcare systems and clinicians who will recommend the device to eligible heart failure patients. The company is venture-backed, having raised approximately $202 million across five disclosed rounds since 2014, with investors including Andera Partners, Novo Holdings, Medtronic, NEA, Gilde Healthcare, Polaris Partners, Elevage Medical Technologies, Lightstone Ventures, Gimv, Seventure Partners, Sands Capital Ventures, Longitude Capital, and the Ireland Strategic Investment Fund.

Short descriptiontext

FIRE1 is a Dublin-based medical device company developing the NORM System, an implantable IVC sensor paired with a wearable belt and cloud apps, for physician-directed self-management of heart failure patients by cardiologists and specialists.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
heart failure management, implantable medical devices, remote patient monitoring, cardiac monitoring systems, connected health devices
Industry3 codes
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAI
Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Heart Failure Management Devices
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Once regulatory approval is obtained, the company plans to commercialize its NORM system comprising the implantable IVC sensor and wearable belt components. Revenue will come from device sales and possibly associated monitoring services to healthcare systems.

kpmg.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1NORM
Description

NORM is the company's heart failure management system - a revolutionary medical device platform that includes an implantable sensor, a monitoring belt, and connected mobile applications for patient and clinician use.

fire1foundry.com
Core offering1 text field

FIRE1 develops and sells the NORM System, an investigational heart failure management platform that combines an implantable sensor placed in the inferior vena cava (IVC), a wearable NORM Belt for daily activation, and cloud-connected patient and clinician applications. The system directly measures fluid volume changes in the IVC to provide early warning of worsening heart failure, supporting physician-directed patient self-management.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • NORM received Red Dot Design Awards in both Healthcare Product Design and Innovative Product categories, recognized for technological innovation and simple, futuristic design.
Product overview1 text field

FIRE1 (Foundry Innovation & Research 1 Ltd) is a Dublin, Ireland-based medical device company offering the NORM System, a breakthrough platform for physician-directed patient self-management of heart failure. The NORM System consists of an implantable sensor placed in the inferior vena cava (IVC), a wearable NORM Belt for daily activation and data collection, plus cloud-connected NORM Patient App and NORM Clinician App/Portal. The system directly measures fluid volume changes in the IVC to provide advance warning of worsening heart failure, enabling patients to make lifestyle and medication changes to prevent hospitalization. The NORM Sensor and NORM Belt work together as the core monitoring components, while the patient and clinician apps provide the interface for daily self-management and care team oversight.

Product and service1 record
1NORM System
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

US clinical trial site for FUTURE-HF2 Early Feasibility Study of the FIRE1 System in heart failure patients, located in New York.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

US clinical trial site for FUTURE-HF2 Early Feasibility Study of the FIRE1 System in heart failure patients, located in Durham, North Carolina.

3The Ohio State University
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

US clinical trial site for FUTURE-HF2 Early Feasibility Study of the FIRE1 System in heart failure patients, located in Columbus, Ohio.

fire1foundry.com
4Rochester General Hospital
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

US clinical trial site for FUTURE-HF2 Early Feasibility Study of the FIRE1 System in heart failure patients.

fire1foundry.com
5Royal Bournemouth Hospital
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

UK clinical trial site for the FIRE1 System in heart failure patients, located in Bournemouth, England.

fire1foundry.com
6Golden Jubilee National Hospital
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

UK clinical trial site for the FIRE1 System in heart failure patients, located in Glasgow, Scotland.

fire1foundry.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

UK clinical trial site for the FIRE1 System in heart failure patients, located in London.

8University Medical Center Groningen
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

European clinical trial site for the FIRE1 System in heart failure patients, located in Groningen, The Netherlands.

fire1foundry.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

European clinical trial site for the FIRE1 System in heart failure patients, located in Rotterdam, The Netherlands.

10University Hospital Galway
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

European clinical trial site for the FIRE1 System in heart failure patients, located in Galway, Ireland.

fire1foundry.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

The Foundry in Menlo Park, California is the medical device incubator where FIRE1 originated. It is a leading medical device incubator that provided the foundation for FIRE1's founding and early development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Abbott
TypeDirect peer
Description

Abbott markets the CardioMEMS HF System, an FDA-approved implantable pulmonary artery pressure sensor for remote heart failure monitoring. CardioMEMS is FIRE1's most direct competitor and the current standard-of-care that FIRE1 must displace in the implantable HF monitoring category.

TypeDirect peer
Description

Israeli medtech developing the V-LAP left atrial pressure sensor, an implantable wireless monitor for heart failure patients. Closest competitor to FIRE1 in the implantable HF hemodynamic monitoring space, with a different anatomical measurement site but overlapping patient population and use case.

TypeBroad incumbent
Description

Medtronic has the HeartLogic diagnostic algorithm embedded in ICDs/CIEDs for heart failure decompensation detection. Although also an investor in FIRE1, Medtronic is both a strategic partner and a competitor with broader cardiac device portfolio and established hospital salesforce.

TypeBroad incumbent
Description

Edwards acquired Vectorious's development-stage assets and is a major structural heart player with growing interest in remote HF management. Comparable as a broader cardiac care incumbent with overlapping HF hemodynamic monitoring ambitions.

TypeBroad incumbent
Description

Boston Scientific operates across interventional cardiology and cardiac rhythm management and owns the Preventice ECG remote monitoring business. Comparable as a broad cardiac incumbent with overlapping HF patient touchpoints, though no direct implantable HF pressure monitor.

TypeEmerging player
Description

iRhythm's Zio long-term continuous cardiac monitoring patch serves arrhythmia and emerging HF patient populations. Comparable as a connected cardiac monitoring company with a wearable-to-cloud data model, though its mechanism (ECG) is different from FIRE1's IVC volume approach.

TypeEmerging player
Description

Eko combines AI-enabled digital stethoscopes with cardiac monitoring algorithms, including emerging HF detection capabilities. Comparable as an emerging connected cardiac monitoring player pursuing earlier HF detection via non-invasive approaches.

TypeEmerging player
Description

Corvia is developing the Corvia Atrial Shunt, an interventional implant for HFpEF patients. Comparable as an emerging implantable HF therapeutic targeting a similar patient population and hospital cardiology channel as FIRE1.

TypeEmerging player
Description

Israeli company developing the ReDS lung fluid measurement system, a non-invasive radar-based thoracic fluid monitor for HF patients. Comparable as an emerging HF monitoring competitor with a contrasting non-invasive mechanism targeting the same clinical use case.

10Qura Inc.
TypeEmerging player
Description

Qura is developing an implantable wireless pulmonary artery pressure sensor for heart failure monitoring. Closest emerging direct peer to CardioMEMS and FIRE1, pursuing an adjacent anatomical measurement site with overlapping clinical and commercial use case.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FIRE1

Heart Failure Management Devicesfire1foundry.com

FIRE1 is a Dublin-based medical device company developing the NORM System, an implantable IVC sensor paired with a wearable belt and cloud apps, for physician-directed self-management of heart failure patients by cardiologists and specialists.

What FIRE1 does

FIRE1 (legal entity Foundry Innovation & Research 1, Limited) is a privately held medical device company headquartered in Dublin, Ireland, developing the NORM System for physician-directed self-management of heart failure. The NORM platform comprises an implantable sensor placed in the inferior vena cava (IVC) that directly measures cross-sectional area changes as a proxy for intravascular fluid volume, a wearable NORM Belt worn briefly each day to activate the sensor and wirelessly transmit data, and cloud-connected NORM Patient and Clinician Apps that surface daily readings and intervention alerts. Unlike pressure-based cardiac monitoring approaches, NORM's direct IVC-area measurement is positioned as a first-in-class mechanism for detecting early fluid accumulation, enabling lifestyle and medication adjustments to prevent decompensation and hospitalization.

The company targets two end-user segments: heart failure patients (particularly those over 65, the population driving most heart failure hospitalizations) and the cardiologists and heart failure specialists who manage them. FIRE1 conducts clinical trials across the US (Columbia, Duke, Ohio State, Rochester General, St David's), the UK (Royal Bournemouth, Golden Jubilee, Royal Brompton, University Hospitals Leicester), Ireland (University Hospital Galway), and the Netherlands (University Medical Center Groningen, Erasmus), building evidence for future regulatory submissions. The product remains investigational and is not yet approved for clinical use in any geography, so no commercial revenue is currently generated.

FIRE1's revenue model is expected to be hardware-led once regulatory approval is secured: device sales of the NORM System (sensor plus belt) to healthcare systems and cardiac catheterization labs, with possible associated monitoring services. The go-to-market approach targets healthcare systems and clinicians who will recommend the device to eligible heart failure patients. The company is venture-backed, having raised approximately $202 million across five disclosed rounds since 2014, with investors including Andera Partners, Novo Holdings, Medtronic, NEA, Gilde Healthcare, Polaris Partners, Elevage Medical Technologies, Lightstone Ventures, Gimv, Seventure Partners, Sands Capital Ventures, Longitude Capital, and the Ireland Strategic Investment Fund.

FIRE1 firmographics

Firmographics
Name
FIRE1
Legal name
Foundry Innovation & Research 1, Limited
Website
https://fire1foundry.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
101–250 employees
Short description
FIRE1 is a Dublin-based medical device company developing the NORM System, an implantable IVC sensor paired with a wearable belt and cloud apps, for physician-directed self-management of heart failure patients by cardiologists and specialists.
Ownership category
akta.pro rank

FIRE1 industry classification

Industry
Product category
Heart Failure Management Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLACAPAB
Connected Medical Devices & Wearables (Sensors, Patches, Implantables)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLAHACAI
Chronic Disease Remote Monitoring (COPD/CHF/HTN, Weight & Symptom Tracking)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Heart failure management
  • Implantable medical devices
  • Remote patient monitoring
  • Cardiac monitoring systems
  • Connected health devices

Where FIRE1 is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices1 record

Markets served

FIRE1 business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Once regulatory approval is obtained, the company plans to commercialize its NORM system comprising the implantable IVC sensor and wearable belt components. Revenue will come from device sales and possibly associated monitoring services to healthcare systems.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

FIRE1 product offering

Product offering

Core offering

FIRE1 develops and sells the NORM System, an investigational heart failure management platform that combines an implantable sensor placed in the inferior vena cava (IVC), a wearable NORM Belt for daily activation, and cloud-connected patient and clinician applications. The system directly measures fluid volume changes in the IVC to provide early warning of worsening heart failure, supporting physician-directed patient self-management.

Product overview

FIRE1 (Foundry Innovation & Research 1 Ltd) is a Dublin, Ireland-based medical device company offering the NORM System, a breakthrough platform for physician-directed patient self-management of heart failure. The NORM System consists of an implantable sensor placed in the inferior vena cava (IVC), a wearable NORM Belt for daily activation and data collection, plus cloud-connected NORM Patient App and NORM Clinician App/Portal. The system directly measures fluid volume changes in the IVC to provide advance warning of worsening heart failure, enabling patients to make lifestyle and medication changes to prevent hospitalization. The NORM Sensor and NORM Belt work together as the core monitoring components, while the patient and clinician apps provide the interface for daily self-management and care team oversight.

Differentiator

Problem solved

Functional benefit

Brands

  • NORM: NORM is the company's heart failure management system - a revolutionary medical device platform that includes an implantable sensor, a monitoring belt, and connected mobile applications for patient and clinician use.

Products and services

  • NORM System

Quantifiable outcome

  • NORM received Red Dot Design Awards in both Healthcare Product Design and Innovative Product categories, recognized for technological innovation and simple, futuristic design.

Companies that use FIRE1

Customer profile

Named customers12 records

Segments2 records

Ideal customer profiles1 record

FIRE1 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

FIRE1 partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered major and core.

  • Columbia University Irving Medical CentermajorStrategic or Co-development Partner · 1 January 2024US clinical trial site for FUTURE-HF2 Early Feasibility Study of the FIRE1 System in heart failure patients, located in New York.
  • Duke University Health SystemmajorStrategic or Co-development Partner · 1 January 2024US clinical trial site for FUTURE-HF2 Early Feasibility Study of the FIRE1 System in heart failure patients, located in Durham, North Carolina.
  • The Ohio State UniversitymajorStrategic or Co-development Partner · 1 January 2024US clinical trial site for FUTURE-HF2 Early Feasibility Study of the FIRE1 System in heart failure patients, located in Columbus, Ohio.
  • Rochester General HospitalmajorStrategic or Co-development Partner · 1 January 2024US clinical trial site for FUTURE-HF2 Early Feasibility Study of the FIRE1 System in heart failure patients.
  • Royal Bournemouth HospitalmajorStrategic or Co-development Partner · 1 January 2024UK clinical trial site for the FIRE1 System in heart failure patients, located in Bournemouth, England.
  • Golden Jubilee National HospitalmajorStrategic or Co-development Partner · 1 January 2024UK clinical trial site for the FIRE1 System in heart failure patients, located in Glasgow, Scotland.
  • Royal Brompton and Harefield HospitalsmajorStrategic or Co-development Partner · 1 January 2024UK clinical trial site for the FIRE1 System in heart failure patients, located in London.
  • University Medical Center GroningenmajorStrategic or Co-development Partner · 1 January 2024European clinical trial site for the FIRE1 System in heart failure patients, located in Groningen, The Netherlands.
  • Erasmus University Medical CentermajorStrategic or Co-development Partner · 1 January 2024European clinical trial site for the FIRE1 System in heart failure patients, located in Rotterdam, The Netherlands.
  • University Hospital GalwaymajorStrategic or Co-development Partner · 1 January 2024European clinical trial site for the FIRE1 System in heart failure patients, located in Galway, Ireland.
  • The FoundrycoreStrategic or Co-development Partner · 1 January 2024The Foundry in Menlo Park, California is the medical device incubator where FIRE1 originated. It is a leading medical device incubator that provided the foundation for FIRE1's founding and early development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

FIRE1 competitors and assessment

Company assessment

Direct peers

  • Abbott: Abbott markets the CardioMEMS HF System, an FDA-approved implantable pulmonary artery pressure sensor for remote heart failure monitoring. CardioMEMS is FIRE1's most direct competitor and the current standard-of-care that FIRE1 must displace in the implantable HF monitoring category.
  • Vectorious Medical Technologies: Israeli medtech developing the V-LAP left atrial pressure sensor, an implantable wireless monitor for heart failure patients. Closest competitor to FIRE1 in the implantable HF hemodynamic monitoring space, with a different anatomical measurement site but overlapping patient population and use case.

Broad incumbents

  • Medtronic: Medtronic has the HeartLogic diagnostic algorithm embedded in ICDs/CIEDs for heart failure decompensation detection. Although also an investor in FIRE1, Medtronic is both a strategic partner and a competitor with broader cardiac device portfolio and established hospital salesforce.
  • Edwards Lifesciences: Edwards acquired Vectorious's development-stage assets and is a major structural heart player with growing interest in remote HF management. Comparable as a broader cardiac care incumbent with overlapping HF hemodynamic monitoring ambitions.
  • Boston Scientific: Boston Scientific operates across interventional cardiology and cardiac rhythm management and owns the Preventice ECG remote monitoring business. Comparable as a broad cardiac incumbent with overlapping HF patient touchpoints, though no direct implantable HF pressure monitor.

Emerging players

  • iRhythm Technologies: iRhythm's Zio long-term continuous cardiac monitoring patch serves arrhythmia and emerging HF patient populations. Comparable as a connected cardiac monitoring company with a wearable-to-cloud data model, though its mechanism (ECG) is different from FIRE1's IVC volume approach.
  • Eko Health: Eko combines AI-enabled digital stethoscopes with cardiac monitoring algorithms, including emerging HF detection capabilities. Comparable as an emerging connected cardiac monitoring player pursuing earlier HF detection via non-invasive approaches.
  • Corvia Medical: Corvia is developing the Corvia Atrial Shunt, an interventional implant for HFpEF patients. Comparable as an emerging implantable HF therapeutic targeting a similar patient population and hospital cardiology channel as FIRE1.
  • Sensible Medical Innovations: Israeli company developing the ReDS lung fluid measurement system, a non-invasive radar-based thoracic fluid monitor for HF patients. Comparable as an emerging HF monitoring competitor with a contrasting non-invasive mechanism targeting the same clinical use case.
  • Qura Inc. Qura is developing an implantable wireless pulmonary artery pressure sensor for heart failure monitoring. Closest emerging direct peer to CardioMEMS and FIRE1, pursuing an adjacent anatomical measurement site with overlapping clinical and commercial use case.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

FIRE1 social profiles

Digital presence

FIRE1 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FIRE1 leadership team

Management profile

Number of profiles

Profiles5 records

FIRE1 funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FIRE1 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FIRE1

What does FIRE1 do?

FIRE1 develops and sells the NORM System, an investigational heart failure management platform that combines an implantable sensor placed in the inferior vena cava (IVC), a wearable NORM Belt for daily activation, and cloud-connected patient and clinician applications. The system directly measures fluid volume changes in the IVC to provide early warning of worsening heart failure, supporting physician-directed patient self-management.

Is FIRE1 a public or private company?

FIRE1 is a private company. It is classified as venture growth investor backed and is currently operating.

When was FIRE1 founded?

FIRE1 was founded in 2016. It employs 101 to 250 people.

Where is FIRE1 based?

FIRE1 is headquartered in Dublin, Ireland, in the Europe region.

How does FIRE1 make money?

One revenue line is on record: medical Device Sales.

Who are FIRE1's main competitors?

Direct peers on record are Abbott and Vectorious Medical Technologies. Broad incumbents are Medtronic, Edwards Lifesciences and Boston Scientific. Emerging players are iRhythm Technologies, Eko Health, Corvia Medical, Sensible Medical Innovations and Qura Inc..

Does FIRE1 have an API?

No public API is recorded for FIRE1.

What industry is FIRE1 in?

FIRE1's product category is Heart Failure Management Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFIRE1 Announces First Patient Implant in the NORM-HF Pivotal Trial Evaluating a New Physiologic Approach to Heart Failure ManagementFIRE1 announced the first patient enrollment in the NORM-HF pivotal trial, an international randomized study evaluating daily IVC monitoring and physician-directed self-management for heart failure. Approximately 800 patients will be randomized, with the primary endpoint being a composite of worsening heart failure events and cardiovascular mortality.BioWorldAndera, Novo lead $25M financing for Fire1Andera Partners and Novo Holdings led a $25 million financing round for Fire1 Ltd., with existing investors including Medtronic and New Enterprise Associates. The funds will accelerate development of Fire1's remote monitoring technology for heart failure patients.IrishtechnewsIreland Defies Global VC Slump with Record €491M Lifesciences & Health Tech VC InvestmentIrish lifesciences and health tech companies raised a record €491.3 million across 89 VC deals in 2024, marking the country's strongest year ever and a new decade high, according to a report by Enterprise Ireland powered by PitchBook data. Enterprise Ireland participated in 60 deals to become the world's most active lifesciences and health tech investor, while late-stage and venture-growth deals surged to 46% of total volume, more than double the 2014 proportion. The sector's momentum continued into 2025 with FIRE1 closing a $120 million late-stage megadeal, one of Europe's largest health tech rounds this year.Digital HealthIreland hits record €491m health tech VC investmentIrish life sciences and health tech companies set a decade-high record in 2024, raising €491.3 million across 89 venture capital deals, with late-stage and venture-growth deals surging to 46% of total volume, more than double the proportion recorded in 2014. Enterprise Ireland emerged as the world's most active life sciences and health tech investor in 2024, participating in 60 deals, while Dublin-based medical device firm FIRE1 secured €115 million in a late-stage funding round in 2025, representing one of the largest health tech rounds in Europe that year. Ireland hosts over 700 life sciences and health tech firms including nine of the world's top 10 MedTech multinationals and is the second-largest MedTech exporter in Europe after Switzerland, with exports valued at €16 billion annually.MedicalstartupsTop 57 Remote Patient Monitoring startups 2025The article lists the top 57 remote patient monitoring startups for 2025, highlighting their innovations and funding amounts. Companies like Biofourmis, Huma, and Fire1 are noted for developing technologies that enable real-time patient health monitoring through wearable devices and mobile health apps. The report underscores a growing trend in healthcare towards remote monitoring solutions that are shaping preventative care.The Irish TimesIrish companies using cutting-edge technology to help patients manage their illnesses at homeIrish medtech firms SymPhysis, Fire1, and Vantive are developing home-care devices for cancer, heart failure, and dialysis. SymPhysis raised €9.2M, Fire1 $213M, and Vantive expects home dialysis to save 624 hours per patient annually. The trend aims to reduce hospital visits and costs.DealformaMedTech, Device, Digital Health, and Wearables M&A and Ventures – Q1 2025Q1 2025 saw a surge in MedTech, device, digital health, and wearables M&A activity, with 24 deals valued at $8.1 billion including $7.6 billion in upfront cash, up from 21 deals totaling $4.2 billion in Q4 2024. Notable acquisitions included Stryker's $4.9 billion buyout of Inari Medical, Zimmer Biomet's $1.2 billion acquisition of Paragon 28, and Boston Scientific's deals for Bolt Medical (up to $900 million) and SoniVie (up to $600 million). Venture funding also accelerated with 63 rounds raising $2.9 billion, more than double the $1.3 billion raised across 49 rounds in Q4 2024, with top raises including BVI Medical's $1 billion round and three $120 million rounds for Supira Medical, FIRE1, and CeQur.Pulse 2.0FIRE1: $120 Million Funding Raised For Transforming Heart Failure CareFIRE1 raised $120 million in a financing round led by Polaris Partners and Elevage Medical Technologies, with new investors Sands Capital and Longitude Capital. The funds will support a pivotal clinical trial of its Norm heart failure management system, which received FDA Breakthrough Device Designation.Business Wire BlogFIRE1 Secures $120 Million Financing to Revolutionize Heart Failure CareFIRE1 completed a $120 million financing round led by Polaris Partners and Elevage Medical Technologies to accelerate its Norm heart failure management system. The company also received FDA Breakthrough Device Designation and will use the funds to complete a pivotal clinical trial.YahooFIRE1 Secures $120 Million Financing to Revolutionize Heart Failure CareFIRE1 completed a $120 million financing round led by Polaris Partners and Elevage Medical Technologies to accelerate its Norm heart failure management system. The company also received FDA Breakthrough Device Designation and will use the funds to complete a pivotal clinical trial.